Drug Trial Radar · NCT01709136
Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity
Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Dec 2005
Primary completion
Jan 2010
Study completion Jan 2010
Sponsor
- Lead sponsor
- University of PittsburghAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pharmacokinetics of Tacrolimus and Sirolimus alone and in combination in liver transplant recipients.
Conditions
- Hypertension
Interventions
SirolimusDrug
Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early and Late Pharmacokinetics of Sirolimus (SRL)Time frame: 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.